# Lilly's Mystery Patient And The Road To 70 Billion - Podcast Intelligence - Week of June 29, 2026

> Operators and analysts on the podcast tape for the week of June 22-29, 2026 weigh Lilly's retatrutide compassionate-use story, a tirzepatide franchise printing 12.8 billion dollars a quarter, and a fragile Medicare obesity on-ramp.

## Podcast Intelligence

### Week of June 29, 2026: Lilly's Mystery Patient And The Road To 70 Billion

---

The loudest story of the week wasn't a trial readout. It was a single, "seemingly well-connected" 79-year-old who somehow got Lilly's unapproved triple-agonist before anyone else on earth. The tape this week was a study in asymmetry: Lilly pulling away on every axis the market cares about, Novo getting cheaper and quieter, and a payer backdrop that keeps reminding you the bottleneck was never the molecule.

## TL;DR

- **Lilly's retatrutide compassionate-use story is a governance flag, not a clinical one**, the drug's efficacy is the least controversial thing about it.
- **The franchise math got bigger again:** tirzepatide already the world's #1 drug at $12.8B/quarter, with a sell-side line of sight to "biggest drug ever."
- **Medicare's obesity on-ramp is real but fragile**, the Bridge program launches July 1, the more permanent Balance model is dead, and the cliff is end-2027.

## What's new

**Lilly opened a compassionate-use door for exactly one person, and won't say who.** On [The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhPzhtNoB-2Bqlg7tjm7aUNQFDQXz2YItfzuVKURplPMJV9qL6u0uAPqB7Nk027j4By0WCJQW-2BbREA5j-2FPEzigaB9s8lZUaAgn5e6fbnnVPl8cQ-3D-3D_gFc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvTdzfoVK2DSnxjU1ducV16cQQJnkl7oRLplWLGgeGF8mvGenkuxnPyzaCK5qvYw2PavkFtIXUcZB7r0PdKBM6IniSHc3M242D4R7hoAivfhiLfksEesYCKWf4OGF0ab3bc0olcAiOMG6a5wYYpmbZ3w-3D) (Jun 25), STAT's Lizzie Lawrence reported that Lilly and the FDA let one 79-year-old man with pulmonary hypertension and severe obesity receive retatrutide via the Compassionate Use Program. The White House, after publication, said it is not President Trump. The substance for investors isn't the celebrity guessing game; it's that, per Lawrence, "with Lilly or Novo Nordisk's previous obesity drugs, they'd never opened a compassionate use program," and Lilly posted it on clinicaltrials.gov "with no listing of the condition, no information about who might qualify." Obesity doc Angela Fitch noted "there's 40 million people this could apply to" and that she got no reply when she asked about her own non-responders. The ethical pressure, Lawrence said, sits "more on Lily's side," a discretion-and-access question heading into a launch.

**The franchise number that actually moves the model.** Trade press [Citeline / Scrip](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgaK3KwKymSh-2FoTad1NRtqYMERPGaHNyiDhrAtu1cG53r8DtSXQSh5I6-2BA03aq9m8lDAGIVG44StrY57qo5SBBavhKoUWJvJS0BslZnQq8owQ-3D-3D81XX_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvYmRBRqeGIn16M-2B3ce3SYA3rg1Fujz0sDModscg9O83hUwXyIf0-2B6UORKBGaFfuy9eiP2QCLsC7D-2Fg7lHMlIrWUft6f0kmPqojX0N3yAolvkGb5yV0lIPTKD4kp-2FID5HNhr4kYaoEL1xas-2FESm5ix-2FM-3D) (Jun 22, Edwin Elmhurst) flagged that Mounjaro hit $8.66B in Q1 2026, more than doubling YoY, overtaking Keytruda as the world's best-selling drug for the first time since early 2023. With Zepbound's $4.16B, the tirzepatide franchise printed $12.8B in a single quarter, with ex-US Mounjaro sales overtaking the US. The following week's [Citeline / Scrip](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg2-2Bm11bwc0KU-2F1n-2FVaedNkSThGgC2Mt9cVyQVoaouRrzRc66PwNhmYQXr50V7JqIQhU1TPSH4cjVLhw-2F1I5DFsgc9WK9psVv-2B2FY29-2Fa7Zng-3D-3DrIh-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvTCABo-2BxihsrMVdTMXnYGlaVkDpu9OBxWfIrxM91hpNNPyjVGjszPlvi8XMxQGA5By0NaVznjbkkCRBinYJDzwx5BhAMQubXA1PpNCRNF15mcj1FKMEizmk4lyflGCy-2BAfGUAX6YJAAVYImAUfqTEro-3D) (Jun 29, Ian Haydock) cited Evaluate's 2026 World Preview projecting tirzepatide above $70B by 2032, "the biggest drug ever," with Lilly at ~$137B in annual drug sales, roughly 60% ahead of #2 AbbVie. Same report: Novo's Ozempic and Wegovy slip out of the 2032 top ten.

**Retatrutide's efficacy is bariatric-surgery-adjacent, and so are its side effects.** Operator color from obesity physician Matthea Rentea on [The Obesity Guide](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiV2zqYIFaqCn10B5qpbhhWay8Y75Qa3q-2BixTCstrPHO5x7XxkvvvglvWfRE9W5J8DYWr-2BBLVMkSO9PRzjGm5R-2Fi1D5PIkzfS-2FcP7iDfk0AVg-3D-3D7xv0_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvckDDGArx7A0BqYJ770YdJK4abpBswZ8hR2RSpDvlzyo25b8WMy1eB0d8oZ3iodMtnXDJVdzpWO5L35WG7CDfC8tfepzcx7XqBLZsCVojYgUNlo0zy2MNuGlxsxQcC0DUEgfTZ-2BUxw233ktZy-2BlciIY-3D) (Jun 22): TRIUMPH-1 showed median 28.3% weight loss at the 12mg dose over 80 weeks, with 62.5% of patients losing 25%+. Her caveat carries the bear seed: vomiting scaled to "about 25%" at the top dose, which she called "an unacceptable tradeoff." Clinical investigator Dr. Juan Pablo Frias, on the Lilly-sponsored [DOC Updates](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhS04n7SAiZkNhORyjYmpC-2F0IDtd4PW02VJ2RIRZTG4JxVFOELwWe5ftKNpi8rEeLXI8O72yEyVcI9Ae4ZkgutewTgFwhyQ-2BLP3pJzh4O8PQw-3D-3D8Fjp_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvewMZpWEBkhrX9ZxTYtIHrCYn62ZV0ukIlAAZ1k7xk5SGrVAQXoqr7TPQkPxCR4hWc-2FH0gPbyGLMOoRF-2BukkdQvqzjoJ82TvBhs4yedZEyOeu1iA9XoG1cVDXqznMLhUAojVWVhi1zD6TIpqgpyHqxU-3D) pipeline episode (Jun 25), put 104-week retatrutide at ~30% average, with meaningful improvement in knee pain and obstructive sleep apnea.

**Medicare cracks the door, barely.** Vanderbilt's Stacie Dusetzina on [NEJM Interviews](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjk9XmTMNu2o7EDblubrzURPcMUUbdvR5Kk4Svq9Ee0o9CoBl-2BZi-2BVb1Eu-2B2ciZtetIDUoHwnMAWjJbVAfDshHQ-2BNX8j0Vdis25NssN2cD2hQ-3D-3D1DUj_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvfZso2WltBYuFLOR4flVppCEKyMh8fnW4fMeUsDRaO5z6vlMuhw-2FZBvzTFsc5lO4JUJ10PXhYvquOuEoHrw84jYDzgbEqxKP-2B-2Be324Uaa4OSwMMNXNKlp9Ca7almMBiMJhOVEZvANZHezD-2F4RqoyGaY-3D) (Jun 24) detailed the GLP-1 Bridge program launching July 1, but it runs entirely outside Part D, the government pays directly, and the more durable Balance model is on hold because "Part D plan sponsors... were not interested in participating." Bridge now sunsets end-2027, the claims process is multi-step, and awareness is "quite low," so expect "a really slow start." The cliff: if Bridge ends, cash price reverts to "more like $350 a month" from $50.

## The debate

**Bull (well voiced this week).** Lilly is compounding a structural lead on efficacy, scale, and economics. Tirzepatide is already #1 globally, retatrutide is approaching surgical weight loss, and the label keeps widening into OSA, CKD and cardiometabolic risk. On [Transform NOW](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhydXULcClF0X-2B14vpw-2F6AL93aoMoqrK2u-2B6YLLqBWCS2B-2FV0Zrt-2BCTpm8-2FbjcnGEV9VDIqzrabiHfe-2B3zY4dUCwiZ6CZTDSLe9FRGpr20MwA-3D-3DPih5_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvSIHEXJMcvDsLmPUoCpKgxtXdc0ZWdKp27hSpjMYhci2pZTkpSrb3Wg74vZIO-2BSeI-2F4Zf-2B6j3GXkIEyzCacJjHE1f7sAWcR5qtELX22uxKI40jv3Bj2pKoXFhkQP0wIMrbNYkQILplcNfStttGa6oh8-3D) (Jun 23) a Lilly executive framed LillyDirect as eliminating "pain points. Like prior auth," a cash-pay channel that routes around the very PBM friction described elsewhere this week.

**Bear (also voiced, from two angles).** First, durability: on [For the Love of Health](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOi37cKO3TYu4t8RVV4dG-2BwDeFv-2BExcAAAkI9M-2Biubey-2FOgsdIm07-2BMbGP5teyoajypxeyfXBdWQV2gCvVituxe2F9Vp26sKc6toCd2jb92DwQ-3D-3DtdTC_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvTnadl9SBYmDJolpdfKr1qG2mnCyYtexLnNLgbf-2FVD1jb0-2F5qFwvH8hD0fD-2BsZE-2BWcAkTXKFtGpOEmONrH99TYZack-2B-2BdxSdRTs8bMf5Pp2d6gv0A9ejgJqueEv72wn9SxdGgxbYFg-2Flj7LncOCPfw0-3D) (Jun 25), Christiana Care's Dr. Lisa Breslow said "the majority regain all of their weight by two years" off-drug, "this is a forever medication," with ~15% non-responders. Second, mechanism fatigue: MetSera CEO Whit Bernard, on [Running Through Walls](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOissi7CtTciN2JzJO3lRXyF1UmUHMnFeuBC3grAdrVPIS1wadCx-2Fr3BB18xDbmh2eTHyeQpQkHT3QJuHhH2vUpYfYfvUbRQcYyEJEL4SzAG9A-3D-3DVSlA_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvXBFka-2FDHTsqXM11YZ-2FGJI0wF6OB0d-2BDRWZvgdyni1rzrmWsJ0kxahJjW6Lko44bXlej82956mFwvWjKjb7nxnATHxo66Q-2FpfOLD9r2YefzaDhZ2SgusbMtN526-2FM1C1ieNCNFHxvWAVa-2BxAcAENbgw-3D) (Jun 23), flagged that in the SURMOUNT-1 extension weight stays flat, then "year three, year four, you start to see this uptick again," which he attributes to "some level of adaptation to the mechanism. The jury's out."

## The names in play

**Novo Nordisk (NVO).** The week's only stock explicitly debated on its merits. On [Wall Street Wildlife](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhBfyTu3jdIhx-2FswqgEmVRVTOZt-2FrtT-2FaYTzsRTeAxitZSWDlUmbQZ0msYDj7HJoPcDbQqw-2BFe2sJUcPtTlPwJSogGOBbiFbWxCw7u5VDp7aQ-3D-3DNz9K_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvdubuWcAXSQ7syM2kTAbVrLWPe41LD9-2Bzxy5irUbRqeqrMSRTms2948rbPhidJA0RFI6JIBik81T49tZHqRGEQRIGcFnujiLbStSb6zabZZWXxj-2BFrxbZSD3o0L62r1pqDuf0GGzbMNem8zwDNrsBiI-3D) (Jun 28), Luke Hallard (an NVO holder) sized the market at "60-40 in Eli Lilly's favor," recapped CagriSema's February head-to-head loss that took the stock down "about 15% in a day," and laid out the deep-value case: NVO around 10x earnings vs Lilly's ~40x, ~$2.3B of buybacks, 9,000 job cuts. His own verdict was honest, "a beaten down tough holding." The silver lining stays on the diabetes side, where Frias confirmed CagriSema's 12-14% weight reduction in T2D.

## Read-throughs

- **Fast-followers / M&A.** Bernard's MetSera saga, Pfizer won, then Novo "put in a topping bid, which... really just doesn't happen in biopharma," shows the majors paying up for differentiated PK rather than building. Frias mapped the chasing pack: Amgen's once-monthly MariTide (now Phase 3), Boehringer's cervodutide (12-15%, outsized liver benefit), and Roche's petrelintide (10%+ with near-placebo tolerability). Watch trial-design risk: Citeline noted placebo-arm contamination (16% of the Synchronize-1 placebo arm secretly on GLP-1s) is muddying competitor readouts.
- **Sleep apnea (RMD, INSP).** No device episode aired, but two clinician sources reinforce the obesity-into-OSA migration: retatrutide's TRIUMPH-1 AHI benefit, and on [The Tell-Tale Heart](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiPHIR2xScV8dmdTqBUdKsbrPNMjGQdvxvs4Qs-2FCXmywWl1UrDbi9NI-2BDyP8PFYz2Yof5A1LmTNhpdUY0yRHKfgejil4iLQhfEMMsprKJtJoA-3D-3Dgej-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvcyOYDOFMe5MGO5yN2-2BoQbZNRKrfxjpmWktVKd7n9f1ZSor2yN0nzc-2FFDJxDa1KxiK-2Ba6JjMDUqSB4yG-2BduFJA5-2BI79GhIqKhZeBxi10hdQuD69PPDKEYvA12LgG8Ma5oRF6w9YhHazgA4JQ4Yat3so-3D) (Jun 24) a pharmacist adding OSA to her practice agreement "because now we have a medication that's approved for it, which is Zep[bound]."
- **Packaged food (MDLZ, HSY vs GIS, KHC, CAG, CPB).** Evercore analysts on [The Real Eisman Playbook](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgcwLMYYWL0CRVGgE-2FROZGBi7ojzcfCbyLccZGP5wQX8bduLmJrDbL-2Bbtlfv8mw5U86znZL4LnZzZlGwPlNol1eV7o6Nv4PwEoT9fQAHa1b9Q-3D-3DMOqL_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbX7uazfMnEylyeUd8Zqh4oxOYdAiPWOgf5Nl7QeJngkvcEpAF2-2ByF-2FaVkJZ8IjK7uG0kVtFPVswMjbud47A7EMfZRdt3gir6HLk3yykIZitfNHopHTePnXxzsYRkjTMtXYeVvuqVKM-2BsIXecsvB1ckJaGoYBKfiuZ-2BU85VPA5S3Ne-2BsYkuoFP4tBOLvjvAN5TI-3D) (Jun 22) sized GLP-1 as only "a half a percent headwind," but additive: "calorie consumption is down 2%... year over year," with share bleeding from legacy carb brands to protein. They're long Mondelez and Hershey (cocoa relief into '27) and steer clear of General Mills, Kraft Heinz, Conagra and Campbell, now sub-10x with ~80% payout ratios.